Jan 22 (Reuters) - Corcept Therapeutics said on Thursday a late-stage trial showed its experimental drug in combination with ...

"The addition of relacorilant to nab-paclitaxel, a trusted and effective chemotherapy, is positioned to become a new standard ...

For women, ovarian cancer is one of the most feared of all diagnoses. Sneaking up silently, often with few symptoms, the ...

Shares of Corcept Therapeutics CORT were up 13.7% on Jan. 22, after the company announced that the phase III ROSELLA study, ...

Differentiating palliative care from hospice is crucial; palliative care focuses on holistic treatment, while hospice ...

Women with certain genetic mutations are at extremely high risk of ovarian cancer. Now, some researchers are trying a new ...

Patients will be able to find out whether they have genes linked to cancer using a world-leading tool developed by the NHS.

Geoff Dick has raised the cash to pay for sport therapy sessions at Marie Curie Hospice following the death of his wife ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept Therapeutics (CORT) stock surges after the company said its Phase 3 ROSELLA study for its ovarian cancer drug ...

Corcept Therapeutics’ relacorilant has improved overall survival (OS) in a phase 3 ovarian cancer study, building on interim data published last year and giving the biotech momentum as it heads into ...